If you have chronic obstructive pulmonary disease (COPD), your airways may be inflamed. It may be hard to take deep breaths and get enough oxygen.

Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

Li Qiang, director of the respiratory and critical care medicine department at the hospital, said the patient had over 10 ...

Researchers have shown that activation of the protein YAP, which helps tumours grow, differs between two- and three-dimensional culture models, pointing to more predictive systems for testing cancer ...

Small-cell lung cancer (SCLC) is one of the most aggressive and deadly types of cancer, often linked to smoking. Although it ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Jon Giles, MD, speaks to the power of personalized medicine and multidisciplinary care to enhance treatment for patients with ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer—particularly those with specific HER2 ...

Ivonescimab is the first therapy to achieve statistically significant positive results in a Phase III trial compared with ...